ecm-RV/p53
Advanced Solid Tumors (TP53 mutations)
PreclinicalActive
Key Facts
Indication
Advanced Solid Tumors (TP53 mutations)
Phase
Preclinical
Status
Active
Company
About Vesicor Therapeutics
Vesicor Therapeutics is pioneering a novel drug delivery platform based on engineered cellular microvesicles (ecm) and non-viral RNA vesicles (RV) to deliver therapeutic payloads like p53 mRNA to solid tumors. Its technology aims to overcome key limitations of viral gene therapy, including immunogenicity and payload size constraints. The company is currently in the preclinical stage with its lead program, ecm-RV/p53, targeting advanced solid tumors. As a private, early-stage biotech, Vesicor's success hinges on validating its platform and advancing its first candidate into clinical trials.
View full company profile